Home
Contact Us
Site Map
Search
Mission & Vision
Board of Directors
Executive Management
Collaborations
Company
|
Date
|
Type
Amgen
11/09
License of Right to Use TAP Technology for Undisclosed Target
9/09
License of Right to Use TAP Technology for Undisclosed Target
9/00
Right to test TAP technology
Genentech*
12/08
License of Right to Use TAP Technology for Undisclosed Target
12/05
License of Right to Use TAP Technology for Undisclosed Target
7/05
License of Right to Use TAP Technology for Undisclosed Target
4/05
License of Right to Use TAP Technology for Undisclosed Target
Bayer HealthCare
10/08
License of Right to Use TAP Technology for Undisclosed Target
sanofi-aventis
8/08
Exercise of Option for Expanded Access to ImmunoGen's TAP Technology
10/06
License for Broader Access to ImmunoGen's Humanization Technology
8/06
Second extension of 7/03 research collaboration; release of ImmunoGen from presenting targets
7/03
Research, development, and commercialization collaboration
Biotest
7/06
License of Right to Use TAP Technology for Undisclosed Target; ImmunoGen Has Opt-In Rights
Genentech
5/06
ImmunoGen to develop commercial-scale manufacturing process for T-DM1; amendment of 5/00 HER2 agreement
5/00
License of Right to Use TAP Technology for HER2 target
Biogen Idec
10/04
License of Right to Use TAP Technology for Undisclosed Target
*Genentech, Inc. is a member of the Roche Group.
© 2010 ImmunoGen, Inc.
|
Privacy Policy
|
Usage Policy
Last updated July 7, 2010